LTRN - Lantern Pharma Inc.

2.24
-0.220   -9.821%

Share volume: 287,022
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$2.46
-0.22
-0.09%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 5%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-8.94%
1 Month
81.38%
3 Months
-27.97%
6 Months
-41.36%
1 Year
-35.82%
2 Year
-54.56%
Key data
Stock price
$2.24
P/E Ratio 
0.00
DAY RANGE
$2.16 - $2.45
EPS 
-$1.77
52 WEEK RANGE
$1.11 - $5.74
52 WEEK CHANGE
-$36.36
MARKET CAP 
46.977 M
YIELD 
N/A
SHARES OUTSTANDING 
11.184 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
2.73
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$237,226
AVERAGE 30 VOLUME 
$1,257,744
Company detail
CEO: Panna L. Sharma
Region: US
Website: lanternpharma.com
Employees: 20
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Recent news